Rosuvastatin 5mg Tablets Recalled Due to Manufacturing Deviations
RemedyRepack Inc. voluntarily recalled 132 bottles of Rosuvastatin 5mg tablets nationwide due to current Good Manufacturing Practice deviations. No illnesses or injuries have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II drug recall with no reported illnesses or injuries. The recall is voluntary and precautionary, based on manufacturing process deviations rather than a specific identified product defect. Per the FDA rubric, voluntary precautionary recalls without reported harm are classified as Moderate.
Plain-English summary
RemedyRepack Inc. voluntarily recalled 132 bottles of Rosuvastatin 5mg tablets in 30-count bottles (NDC 70518-3519-00) that were distributed nationwide. The affected lot numbers are J0668398-121422 (expiration 12/31/2023), J0661225-111522, J0654053-101822 (expiration 11/30/2023), and J0646383-091422 (expiration 09/30/2023).
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations identified during the manufacturing process. The FDA classified this as a Class II recall. No illnesses or injuries have been reported related to this product.
Patients who have obtained Rosuvastatin 5mg tablets from the affected lot numbers should consult their healthcare provider or pharmacist to determine if their medication is affected. The firm initiated the recall on March 20, 2023, and the recall was terminated on October 19, 2023.
The recalled product
- Product
- Rosuvastatin 5mg tablets, 30-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC 70518-3519-00
- Manufacturer
- RemedyRepack Inc.
- Hazard
- Affected units
- 132
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot#: J0668398-121422
- Exp. Date 12/31/2023
- J0661225-111522
- J0654053-101822 Exp. Date 11/30/2023
- J0646383-091422
- Exp. Date 09/30/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by RemedyRepack Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · manufacturing deviation
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06